Regulatory Briefs: IVD Draft Guidance; Dispute Panel; Risk Communication

FDA releases draft guidance on human leukocyte antigen test kits. Wright Medical announces its Augment bone graft will go to FDA’s Dispute Resolution Panel. More news.

Labeling for nucleic-acid-based human leukocyte antigen (HLA) test kits should specify the marker the test is intended to detect, and performance studies for the kits should demonstrate “with a high level of confidence” that the kit performs within the established specifications, FDA recommends in a Nov. 20 draft guidance. The guidance applies to HLA test kits used to match donors and recipients in transfusion and transplantation procedures, and explains the types of validation studies and other information FDA wants to see in 510(k) submissions for the kits. It includes specific recommendations for accuracy studies, precision studies and clinical comparison studies, including pointers in each case for the study design, samples and concordance description.

FDA notes that the science and technology behind HLA test kits has become increasingly complex, and that the highly polymorphic human leukocyte antigen system poses “significant and unique challenges” for...

More from Regulation

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.